Cancer detection has advanced significantly recently, and biomarkers have emerged as powerful tools in identifying disease earlier. Understanding how biomarkers work can help patients and healthcare providers make informed decisions about screening and treatment strategies. If you or a loved one has been affected by cancer potentially linked to environmental or occupational exposures, know that support and resources are available for those impacted by toxic exposure-related illnesses.
Published on:
April 1, 2026
Category:
Cancer Diagnosis
A biomarker, short for "biological marker," is an objective measure of a substance or characteristic in the body, at a specific moment. In cancer, biomarkers are molecules, genes, or characteristics that signal the presence of cancer cells or indicate how a cancer might behave.
These markers can exist in various forms, such as proteins produced by tumors, DNA mutations within cancer cells, RNA sequences, metabolites, or physical characteristics visible under a microscope. When cancer develops, it often produces specific biomarkers or changes the levels of existing ones, creating detectable patterns.
Biomarkers can be found in blood, urine, tissue samples, or other body fluids. Some are specific to certain cancer types, while others may be elevated across multiple conditions. It's important to note that elevated biomarker levels don't always mean someone has cancer because noncancerous conditions can sometimes cause increases.
Biomarkers help diagnose cancer when combined with other tests like biopsies or imaging, though elevated levels alone don't confirm cancer. Not everyone with a particular cancer type will have elevated levels of associated markers, which is why biomarker measurements are typically used alongside other diagnostic tools.
Beyond detection, biomarkers help determine cancer type and stage, estimate prognosis, and identify which treatments may be effective. Some biomarkers indicate whether someone is a candidate for particular targeted therapies. These can be measured in tumor tissue samples or through liquid biopsies that detect tumor cells or biological material shed into the blood.
During treatment, periodic biomarker measurements show whether tumors are responding to therapy. After treatment ends, measuring biomarkers periodically can help check for cancer recurrence, enabling earlier intervention if the disease returns.
Many biomarker tests require only a blood draw or urine sample, making testing far less burdensome than surgical biopsies and encouraging regular monitoring.
Biomarkers may detect cancer before symptoms develop or before tumors are visible on scans, often catching the disease at more treatable stages.
Biomarker tests provide numerical measurements that can be tracked over time, helping clinicians make evidence-based decisions.
Biomarkers enable precision medicine by identifying which treatments will most likely benefit individual patients.
Some biomarkers indicate how aggressive a cancer is likely to be, helping patients and doctors make informed decisions about treatment intensity and monitoring.
Many biomarkers can be elevated for reasons unrelated to cancer. Inflammation, benign conditions, and infections may raise biomarker levels, causing unnecessary anxiety and additional testing.
Not all cancers produce elevated biomarker levels, especially in early stages. False negatives can provide dangerous false reassurance, potentially delaying diagnosis.
Biomarker levels vary among individuals based on age, sex, ethnicity, smoking status, and other factors, making interpretation complex.
Not all cancers have reliable biomarkers for detection. While some cancers have established biomarkers, many cancer types lack effective screening tools.
Biomarkers rarely provide definitive diagnoses alone. Abnormal results typically require confirmation through imaging or biopsies.
Examples Relevant to Ovarian Cancer, Mesothelioma, and Non-Hodgkin Lymphoma
Understanding how biomarkers function in specific cancer types illustrates both their potential and practical limitations. Some biomarkers associated with ovarian cancer, mesothelioma, and Non-Hodgkin Lymphoma include:
Ovarian Cancer Biomarkers
CA-125 (Cancer Antigen 125) is the most established biomarker for ovarian cancer. This protein becomes elevated in approximately 80% of advanced ovarian cancers but only about 50% of early-stage cases. CA-125 levels can also rise with endometriosis, pelvic inflammatory disease, and other benign conditions, limiting its usefulness. However, it proves valuable for monitoring high-risk women with BRCA mutations and tracking treatment response.
HE4 (Human Epididymis Protein 4) offers improved specificity over CA-125 for distinguishing malignant from benign pelvic masses. The ROMA (Risk of Ovarian Malignancy Algorithm) score combines CA-125 and HE4 levels with menopausal status for more accurate risk assessment.
Mesothelioma Biomarkers
Mesothelioma, strongly linked to asbestos exposure, typically evades diagnosis until advanced stages. The search for accurate biomarkers for mesothelioma is ongoing. Currently, Mesothelin is the primary biomarker for mesothelioma screening and the only FDA-approved blood-based biomarker for mesothelioma. Released by mesothelioma cells, soluble mesothelin-related peptides (SMRP) can be detected in blood. However, mesothelin can also be elevated in pancreatic cancer and other conditions. Additional biomarkers such as Fibulin-3 and Osteopontin have shown some promise as mesothelioma biomarkers, but research continues.
Non-Hodgkin Lymphoma Biomarkers
Lactate Dehydrogenase (LDH) becomes elevated in many cancers, including non-Hodgkin lymphoma. Higher LDH levels correlate with greater tumor burden and more aggressive disease, providing important prognostic information.
Beta-2 microglobulin indicates higher disease burden and typically correlates with poorer prognosis, helping physicians assess disease severity and plan treatment intensity.
Circulating tumor DNA (ctDNA) represents an emerging frontier in lymphoma monitoring. Liquid biopsy techniques can detect DNA fragments released by lymphoma cells, and may detect relapse earlier than traditional approaches.
Individuals seeking more information about cancer biomarkers should contact trusted organizations that provide evidence-based resources. Additionally, patients should discuss biomarker testing with their healthcare providers to better understand which tests are appropriate for their individual circumstances.
If you or a loved one has been diagnosed with cancer potentially linked to environmental or occupational exposures, such as mesothelioma from asbestos, or other mass tort-related conditions, you don't have to navigate this journey alone. Early detection through biomarker testing is crucial, but so is understanding your legal rights and options. At Injury Info, we connect mass tort victims with the resources and support they need. Contact us to learn more.
Some cancer-causing exposures take decades to cause illness. Learn about cancer latency and how it affects diagnosis.
Learn how meningiomas are diagnosed, what grades mean, and what to expect next, including tests, treatment options, and sources of support.
Understand Parkinson’s staging, common tests, care planning, and supportive resources to help you move forward after a diagnosis.
© 2026, Injury Info. All rights reserved.